A Phase 3 Randomized Study of Loncastuximab Tesirine Combined with Rituximab Versus Immunochemotherapy in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

This study will be conducted in two parts. Part 1 of the study will test if the investigational drug, called loncastuximab tesirine in combination with rituximab, is a safe and effective treatment for DLBCL. Part 2 will compare the combination of loncastuximab tesirine with rituximab (Lonca-R) to a standard treatment regimen for DLBCL: rituximab plus gemcitabine and oxaliplatin (R-GemOx). The purpose of Part 2 is to evaluate whether Lonca-R is more effective than R-GemOx in decreasing the growth and spread of lymphoma, preventing it from coming back quickly and helping patients live longer.